Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis

Article metrics

Abstract

The objective of this study was to assess whether vitamin D (VD) treatment alters the overall all-cause and cardiovascular mortalities in a chronic kidney disease (CKD) population. We systematically searched PubMed, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials without language restriction, until the publication date of 22 February 2016. All related literatures that compared VD treatment with non-VD treatment and reported the mortality of patients with CKD (including those undergoing dialysis) were identified. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated by using the random- and fixed-effects models. Randomised controlled trials (RCTs) that used the intention-to-treat principle and observational studies (OSs) were analysed separately. For this study, 38 studies involving 223 429 patients (17 RCTs, n=1819 and 21 OSs, n=221610) were included. In the OSs, VD treatment was significantly associated with reductions in both all-cause and cardiovascular mortalities; however, such significant association was not found in the RCTs. The existing RCTs do not provide sufficient or precise evidence that VD supplementation affects the mortality of patients with CKD, although subsets of patients that could potentially benefit from VD treatment can be identified by using the existing data from the RCTs. Nevertheless, large-size RCTs are needed in the future to assess any potential differences in survival prospectively.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

References

  1. 1

    Obi Y, Hamano T, Isaka Y . Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease. Dis Markers 2015; 2015: 868961.

  2. 2

    Parikh C, Gutgarts V, Eisenberg E, Melamed ML . Vitamin D and clinical outcomes in dialysis. Semin Dial 2015; 28: 604–609.

  3. 3

    Hanafusa N . Vascular calcification - pathological mechanism and clinical application -. the effect of phosphate binders on vascular calcification. Clin Calcium 2015; 25: 711–721.

  4. 4

    Eddington H, Kalra PA . The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. J Ren Care 2010; 36 (Suppl 1), 61–67.

  5. 5

    Vimaleswaran KS, Cavadino A, Berry DJ, Jorde R, Dieffenbach AK, Lu C et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes Endocrinol 2014; 2: 719–729.

  6. 6

    Jiang WL, Gu HB, Zhang YF, Xia QQ, Qi J, Chen JC . Vitamin D supplementation in the treatment of chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol 2016; 39: 56–61.

  7. 7

    Mann MC, Hobbs AJ, Hemmelgarn BR, Roberts DJ, Ahmed SB, Rabi DM . Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J 2015; 8: 41–48.

  8. 8

    Gracia-Iguacel C, Gallar P, Qureshi AR, Ortega O, Mon C, Ortiz M et al. Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome. J Ren Nutr 2010; 20: 359–367.

  9. 9

    Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024–1032.

  10. 10

    Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G et al. Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 2012; 60: 567–575.

  11. 11

    Zheng Z, Shi H, Jia J, Li D, Lin S . Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 2013; 14: 199.

  12. 12

    Krause R, Schober-Halstenberg HJ, Edenharter G, Haas K, Roth HJ, Frei U . Vitamin D status and mortality of German hemodialysis patients. Anticancer Res 2012; 32: 391–395.

  13. 13

    Canale D, de Bragança AC, Gonçalves JG, Shimizu MH, Sanches TR, Andrade L et al. Vitamin D deficiency aggravates nephrotoxicity, hypertension and dyslipidemia caused by tenofovir: role of oxidative stress and renin-angiotensin system. PLoS One 2014; 9: e103055.

  14. 14

    Iruretagoyena M, Hirigoyen D, Naves R, Burgos PI . Immune response modulation by vitamin D: role in systemic lupus erythematosus. Front Immunol 2015; 6: 513.

  15. 15

    Liu WC, Zheng CM, Lu CL, Lin YF, Shyu JF, Wu CC et al. Vitamin D and immune function in chronic kidney disease. Clin Chim Acta 2015; 450: 135–144.

  16. 16

    Yin K, Agrawal DK . Vitamin D and inflammatory diseases. J Inflamm Res 2014; 7: 69–87.

  17. 17

    Alyami A, Soares MJ, Sherriff JL, Zhao Y, Hallett J, Coombes F . A systematic review protocol examining the effect of vitamin D supplementation on endothelial function. BMJ Open 2015; 5: e006835.

  18. 18

    Sergeev IN . Vitamin D-mediated apoptosis in cancer and obesity. Horm Mol Biol Clin Investig 2014; 20: 43–49.

  19. 19

    Li L, Lin M, Krassilnikova M, Ostrow K, Bader A, Radbill B et al. Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial. PLoS One 2014; 9: e109998.

  20. 20

    Messa P, Cozzolino M, Brancaccio D, Cannella G, Malberti F, Costanzo AM et al. Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrol 2015; 16: 11.

  21. 21

    Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ 2016; 352: i1102.

  22. 22

    Gu WJ, Wang F, Tang L, Liu JC . Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies. Chest 2015; 147: 335–346.

  23. 23

    Memmos DE, Eastwood JB, Talner LB, Gower PE, Curtis JR, Phillips ME et al. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed) 1981; 282: 1919–1924.

  24. 24

    Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358–363.

  25. 25

    Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000; 36: 550–561.

  26. 26

    Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43: 877–890.

  27. 27

    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263–276.

  28. 28

    de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543–1551.

  29. 29

    Marckmann P, Agerskov H, Thineshkumar S, Bladbjerg EM, Sidelmann JJ, Jespersen J et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523–3531.

  30. 30

    Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, Shahid SK et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012; 96: 672–679.

  31. 31

    Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ . Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 1143–1149.

  32. 32

    Delanaye P, Weekers L, Warling X, Moonen M, Smelten N, Médart L et al. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant 2013; 28: 1779–1786.

  33. 33

    Massart A, Debelle FD, Racapé J, Gervy C, Husson C, Dhaene M et al. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. Am J Kidney Dis 2014; 64: 696–705.

  34. 34

    Wasse H, Huang R, Long Q, Zhao Y, Singapuri S, McKinnon W et al. Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study. J Vasc Access 2014; 15: 88–94.

  35. 35

    Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS et al. Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol 2015; 10: 611–619.

  36. 36

    Merino JL, Teruel JL, Fernández-Lucas M, Villafruela JJ, Bueno B, Gomis A et al. Effects of a single, high oral dose of 25-hydroxycholecalciferol on the mineral metabolism markers in hemodialysis patients. Ther Apher Dial 2015; 19: 212–219.

  37. 37

    Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674–684.

  38. 38

    Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH et al. Effect of paricalcitol on left ventricular mass and function in CKD–the OPERA trial. J Am Soc Nephrol 2014; 25: 175–186.

  39. 39

    Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179–184.

  40. 40

    Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–1125.

  41. 41

    Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351–357.

  42. 42

    Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771–780.

  43. 43

    Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B . Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613–1619.

  44. 44

    Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070–1078.

  45. 45

    Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K . Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397–403.

  46. 46

    Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: 1379–1388.

  47. 47

    Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963–972.

  48. 48

    Sugiura S, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 2010; 14: 43–50.

  49. 49

    Tsuneo Konta MD, Masato Hoshikawa MD, Satoshi Takasaki MD, Kazunobu Ichikawa MD, Yusuke Mashima MD, Toshiyuki Takahashi MD et al. Patient survival and the combination of vitamin D and phosphorus binder in dialysis. Dial Transplant 2010; 39: 427–431.

  50. 50

    Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X et al. Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Nephron Clin Pract 2011; 118: c204–c210.

  51. 51

    Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G et al. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood Purif 2011; 32: 124–132.

  52. 52

    Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH?? 150pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant 2012; 27: 3588–3594.

  53. 53

    Ogawa T, Kyono A, Sato M, Sugimoto H, Otsuka K, Nitta K . Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients. Clin Exp Nephrol 2012; 16: 779–785.

  54. 54

    Ogawa M, Ogawa T, Inoue T, Otsuka K, Nitta K . Effect of alfacalcidol therapy on the survival of chronic hemodialysis patients. Ther Apher Dial 2012; 16: 248–253.

  55. 55

    Kerschbaum J, Vychytil A, Lhotta K, Prischl FC, Wiesholzer M, Machhold-Fabrizii V et al. Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PLoS One 2013; 8: e67836.

  56. 56

    Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A . Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events. Am J Ther 2013; 20: 480–486.

  57. 57

    Wu S, Wang J, Wang F, Wang L . Oral active vitamin d treatment and mortality in maintenance hemodialysis patients. Cardiorenal Med 2014; 4: 217–224.

  58. 58

    Shoji T, Marubayashi S, Shigematsu T, Iseki K, Tsubakihara Y . Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients. Ther Apher Dial 2015; 19: 235–244.

Download references

Author information

Correspondence to Y Zhang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading